Refractory microsatellite stable metastatic colorectal cancer with ERBB2/ERBB3 mutation may be preferred population for regorafenib plus PD-1 inhibitor therapy: a real-world study.

Xuan Dai,Wenjun Ding,Yongshan He,Shiyong Huang,Yun Liu,Tingyu Wu

Frontiers in Oncology（2023）

引用 0|浏览1

暂无评分

摘要

Regorafenib in combination with PD-1 inhibitor provides a feasible treatment regimen for refractory MSS mCRC with tolerated toxicity. Patients with ERBB2/ERBB3 mutation may be the preferred population for this combination regimen.

查看译文

关键词

stable metastatic colorectal cancer,erbb2/erbb3 mutation,colorectal cancer,refractory microsatellite,real-world

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要